178 related articles for article (PubMed ID: 22145678)
21. Burden of herpes zoster and postherpetic neuralgia in Japanese adults 60 years of age or older: Results from an observational, prospective, physician practice-based cohort study.
Sato K; Adachi K; Nakamura H; Asano K; Watanabe A; Adachi R; Kiuchi M; Kobayashi K; Matsuki T; Kaise T; Gopala K; Holl K
J Dermatol; 2017 Apr; 44(4):414-422. PubMed ID: 27917531
[TBL] [Abstract][Full Text] [Related]
22. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States.
Meyers JL; Madhwani S; Rausch D; Candrilli SD; Krishnarajah G; Yan S
Hum Vaccin Immunother; 2017 Aug; 13(8):1861-1872. PubMed ID: 28605285
[TBL] [Abstract][Full Text] [Related]
23. Economic Burden of Herpes Zoster ("culebrilla") in Latin America.
Rampakakis E; Pollock C; Vujacich C; Toniolo Neto J; Ortiz Covarrubias A; Monsanto H; Johnson KD
Int J Infect Dis; 2017 May; 58():22-26. PubMed ID: 28267595
[TBL] [Abstract][Full Text] [Related]
24. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
Annemans L; Bresse X; Gobbo C; Papageorgiou M
J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
[TBL] [Abstract][Full Text] [Related]
25. [Herpes Zoster and its prevention in Italy. Scientific consensus statement].
Franco E; Gabutti G; Bonanni P; Conversano M; Stefano Valente ME; Ferro A; Icardi G; Antonio Volpi ML; Maggi S; Rossi A; Scotti S; Vitale F; Greco D;
Ig Sanita Pubbl; 2014; 70(1):111-27. PubMed ID: 24770367
[TBL] [Abstract][Full Text] [Related]
26. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
27. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.
Ultsch B; Köster I; Reinhold T; Siedler A; Krause G; Icks A; Schubert I; Wichmann O
Eur J Health Econ; 2013 Dec; 14(6):1015-26. PubMed ID: 23271349
[TBL] [Abstract][Full Text] [Related]
28. Herpes zoster vaccine: A health economic evaluation for Switzerland.
Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
[TBL] [Abstract][Full Text] [Related]
29. Community and patient values for preventing herpes zoster.
Lieu TA; Ortega-Sanchez I; Ray GT; Rusinak D; Yih WK; Choo PW; Shui I; Kleinman K; Harpaz R; Prosser LA
Pharmacoeconomics; 2008; 26(3):235-49. PubMed ID: 18282017
[TBL] [Abstract][Full Text] [Related]
30. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition.
Harvey M; Prosser LA; Rose AM; Ortega-Sanchez IR; Harpaz R
Pain; 2020 Feb; 161(2):361-368. PubMed ID: 31599852
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of herpes zoster vaccine in Canada.
Najafzadeh M; Marra CA; Galanis E; Patrick DM
Pharmacoeconomics; 2009; 27(12):991-1004. PubMed ID: 19908924
[TBL] [Abstract][Full Text] [Related]
32. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
[No Abstract] [Full Text] [Related]
33. Associations of Perceived Mental Stress, Sense of Purpose in Life, and Negative Life Events With the Risk of Incident Herpes Zoster and Postherpetic Neuralgia: The SHEZ Study.
Takao Y; Okuno Y; Mori Y; Asada H; Yamanishi K; Iso H
Am J Epidemiol; 2018 Feb; 187(2):251-259. PubMed ID: 29036443
[TBL] [Abstract][Full Text] [Related]
34. [Herpes zoster and post-herpetic neuralgia in the elderly: Particularities in prevention, diagnosis, and treatment].
García-González AI; Rosas-Carrasco O
Gac Med Mex; 2017; 153(1):92-101. PubMed ID: 28128811
[TBL] [Abstract][Full Text] [Related]
35. Incidence and disease burden of herpes zoster in the population aged ≥50 years in China: Data from an integrated health care network.
Sun X; Wei Z; Lin H; Jit M; Li Z; Fu C
J Infect; 2021 Feb; 82(2):253-260. PubMed ID: 33359014
[TBL] [Abstract][Full Text] [Related]
36. Herpes zoster in Germany: quantifying the burden of disease.
Ultsch B; Siedler A; Rieck T; Reinhold T; Krause G; Wichmann O
BMC Infect Dis; 2011 Jun; 11():173. PubMed ID: 21679419
[TBL] [Abstract][Full Text] [Related]
37. Herpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database.
Opstelten W; Mauritz JW; de Wit NJ; van Wijck AJ; Stalman WA; van Essen GA
Fam Pract; 2002 Oct; 19(5):471-5. PubMed ID: 12356697
[TBL] [Abstract][Full Text] [Related]
38. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient.
Johnson RW; Wasner G; Saddier P; Baron R
Drugs Aging; 2008; 25(12):991-1006. PubMed ID: 19021299
[TBL] [Abstract][Full Text] [Related]
39. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
